香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《關於 控股子公司簽署許可協議的公告》，僅供參閱。 承董事會命 上海復星醫藥（集團）股份有限公司 董事長 陳玉卿 中國，上海 2025 年6 月3 0 日 於本公告日期，本公司之執行董事為陳玉卿先生、關曉暉女士、文德鏞先生及王可心先生；本公司之非執行 董事為陳啟宇先生、潘東輝先生及吳以芳先生；本公司之獨立非執行董事為余梓山先生、王全弟先生、Chen Penghui先生及楊玉成先生；以及本公司之職工董事為嚴佳女士。 * ...

上海复星医药（集团）股份有限公司 关于控股子公司签署许可协议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：600196 股票简称：复星医药 编号：临 2025-110 重要内容提示 ●协议类型：合作开发、生产及商业化许可等 ●协议内容：复宏汉霖与 FBD 将就 FBD 在研的（1）分子 HCB101（即 SIRPα-Fc 融合蛋白）、及（2）任何含有该分子作为其活性成分的药物于约定许可区域及领域 内（即用于人类疾病治疗）的开发、生产及商业化开展合作。 ●特别风险提示： 1、许可产品于许可区域的临床开发、注册、生产（如有）、商业化等还须得到 相关监管机构（包括但不限于国家药监局等）的批准。根据国内外药品研发经验， 药品研发是项长期工作，需要经过临床前研究、临床试验、注册等诸多环节，具有 不确定性。因此，许可产品于许可区域能否完成相关临床试验、以及能否获得上市 批准，均存在不确定性。 2、许可产品上市后的销售情况可能受到（包括但不限于）用药需求、市场竞争、 销售渠道等因素影响，存在不确定性。 一、本次合作概述 ...

Core Viewpoint - Fosun Pharma's subsidiary, Fuhong Hanlin, has signed a licensing agreement with FBD to collaborate on the development, production, and commercialization of the SIRPα-Fc fusion protein (HCB101) and related drugs in specified regions and fields [1] Group 1: Licensing Agreement Details - The agreement involves Fosun Pharma's subsidiary paying up to $59 million to FBD [1] - Additionally, Fosun Pharma will pay up to $143 million in commercial milestone payments based on the annual net sales of the licensed product in Region 1 [1] Group 2: Market Considerations - The sales performance of the licensed product may be influenced by factors such as drug demand, market competition, and sales channels, indicating potential uncertainties [1]

翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) | 表格類別： | 股票 狀態： 新提交 | | --- | --- | | 公司名稱： | 上海復星醫藥(集團)股份有限公司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (於中華人民共和國註冊成立的股份有限公司) | | 呈交日期： | 2025年6月30日 | 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 A | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《關於 控股子公司擬採納股權激勵計劃的公告》，僅供參閱。 承董事會命 上海復星醫藥（集團）股份有限公司 董事長 陳玉卿 中國，上海 2025 年6 月2 7 日 於本公告日期，本公司之執行董事為陳玉卿先生、關曉暉女士、文德鏞先生及王可心先生；本公司之非執行 董事為陳啟宇先生、潘東輝先生及吳以芳先生；本公司之獨立非執行董事為余梓山先生、王全弟先生、Chen Penghui先生及楊玉成先生；以及本公司之職工董事為嚴佳女士。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) | 表格類別： | 股票 狀態： | 新提交 | | --- | --- | --- | | 公司名稱： | 上海復星醫藥(集團)股份有限公司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (於中華人民共和國註冊成立的股份有限公司) | | | 呈交日期： | 2025年6月27日 | | 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | | 說明 | | | | | ...

Summary of Fosun Pharma Conference Call Company Overview - Fosun Pharma's total revenue for 2024 is approximately 40.3 billion RMB, with innovative drug revenue nearing 8 billion RMB, showing a continuous increase in proportion [2][3] Core Business Segments - The company operates three main business segments: - Pharmaceutical segment: Revenue exceeds 28.9 billion RMB, accounting for over 70% of total revenue [3] - Medical device diagnostics segment: Revenue is 4.3 billion RMB, representing about 10% of total revenue [3] - Medical services segment: Revenue is approximately 7.6 billion RMB, making up nearly 19% of total revenue [3] Innovative Drug Highlights - Innovative drug revenue reached nearly 8 billion RMB in 2024, with core products Hanshuozhuang and Hanquyou generating over 1.3 billion RMB and 2.8 billion RMB, respectively [2][4] - Future growth in innovative drug revenue is expected to maintain a 20% growth rate [2][4] - New products in the pipeline include FCN159 for rare tumors and FCN437 for breast cancer [5][14] Medical Device Diagnostics Segment - The medical device diagnostics segment generated 4.3 billion RMB in 2024, with key products including Assystem's long-acting botulinum toxin and the Da Vinci surgical robot [7] - The segment is currently operating at a loss but is expected to improve with the establishment of a major R&D and training base in Shanghai [7] Medical Services Segment - The medical services segment reported approximately 7.6 billion RMB in revenue for 2024, still operating at a loss but showing significant reduction in losses from 800 million RMB in 2022 to 300 million RMB in 2024 [8] Strategic Initiatives - The company is focusing on innovative drugs and high-value medical devices, having exited non-core assets to recover approximately 3 billion RMB for reinvestment in innovation [2][9] - The leadership team has been restructured, emphasizing innovation and internationalization [10][11] R&D Pipeline and New Products - Notable products in the R&D pipeline include ALK inhibitor Furretinib and PD-1 plus VEGFR combination therapy, with some products entering Phase III clinical trials [6] - The company is actively pursuing best-in-class potential products, with several receiving orphan drug designation [6] Financial Management and Shareholder Value - The company has implemented measures to optimize its debt structure and has conducted stock buybacks to protect investor interests, with 300 million RMB repurchased in A-shares and approximately 45 million HKD in Hong Kong shares [4][12] Conclusion - Fosun Pharma is strategically positioning itself for growth in innovative pharmaceuticals and medical devices while managing its financial health and operational efficiency through asset optimization and leadership restructuring [9][10]

如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) | 表格類別： | 股票 狀態： 新提交 | | --- | --- | | 公司名稱： | 上海復星醫藥(集團)股份有限公司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (於中華人民共和國註冊成立的股份有限公司) | | 呈交日期： | 2025年6月26日 | | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 A | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | ...

Core Viewpoint - The document outlines the information disclosure system of Shanghai Fosun Pharmaceutical (Group) Co., Ltd., emphasizing the importance of timely, accurate, and complete disclosure of information that may significantly impact the trading prices of the company's securities and derivatives. Group 1: General Principles - The information disclosure system is established to regulate the disclosure behavior of the company and related parties, ensuring the protection of the company's and investors' legal rights [1][2] - Information disclosure obligations apply to various parties, including the company's board of directors, senior management, shareholders, and other relevant individuals [2][3] - The board of directors is responsible for implementing the information disclosure system, with the chairman as the primary responsible person [3][4] Group 2: Basic Principles of Information Disclosure - Information must be disclosed in a timely and fair manner, ensuring that all investors receive the same information simultaneously [3][4] - Disclosure must be truthful, accurate, complete, and clear, without any misleading statements or significant omissions [3][4] - The company must adhere to legal and regulatory requirements for information disclosure, including those set by the Shanghai Stock Exchange and the Hong Kong Stock Exchange [4][5] Group 3: Content of Information Disclosure - The company is required to prepare and disclose periodic reports, including annual and interim reports, in accordance with relevant regulations [6][7] - Annual reports must include key information such as the company's basic situation, major accounting data, stock and bond issuance, and significant events during the reporting period [7][8] - The company must disclose any risks that may significantly impact its core competitiveness and future development [7][8] Group 4: Temporary Reports - Temporary reports must be disclosed for significant events that may impact the trading prices of the company's securities, including shareholder and board resolutions [9][10] - The company must immediately disclose any major events that investors are not yet aware of, detailing the cause, current status, and potential impact [9][10] Group 5: Internal Management of Information Disclosure - The board secretary's office is responsible for managing information disclosure, coordinating the collection and reporting of information to the board [13][14] - All departments and subsidiaries must report significant events to the board secretary promptly [18][19] - The company must establish internal procedures for the preparation, review, and disclosure of periodic reports [19][20] Group 6: Confidentiality and Accountability - Information disclosure obligations include maintaining confidentiality of undisclosed information and ensuring that insiders do not leak such information [21][22] - Individuals who fail to comply with disclosure requirements or cause significant omissions may face internal penalties and legal liabilities [22][23]

Core Points - The document outlines the rules for the board of directors of Shanghai Fosun Pharmaceutical (Group) Co., Ltd, aiming to standardize meeting procedures and decision-making processes to enhance governance and decision-making quality [1][3][26] Group 1: Board Structure and Responsibilities - The board of directors is responsible for significant corporate actions, including capital changes, major acquisitions, and internal management structure [3][4] - The board must convene at least four regular meetings annually, with the chairman responsible for calling these meetings [7][10] - The board has the authority to decide on the appointment and remuneration of senior management, including the CEO and other executives [3][5] Group 2: Meeting Procedures - Regular meetings require a minimum of fourteen days' notice, while temporary meetings require three days' notice [11][12] - Proposals for meetings must be clear and submitted with supporting materials [9][10] - Decisions require a majority vote from the attending directors, with specific rules for handling conflicts of interest and ensuring independent director participation [20][22] Group 3: Documentation and Record-Keeping - Meeting records must include details such as date, attendees, agenda, and voting results, and should be signed by participants [23][24] - The board secretary is responsible for maintaining meeting records for ten years and ensuring they are accessible to directors upon request [26][33] - Any resolutions made must be announced according to regulatory requirements, and confidentiality must be maintained until official disclosure [29][30]